Pancreatic Cancer Research

ResearcherShanghai Medical College of Fudan UniversityNo recent work listed

Jinfeng Xiang

Matched on OpenAlex author ID A5112310715. Sources: OpenAlex.

Their work

Papers
12 (first author 1, last author 0)
Trials
0
Grants
0
Labs led
0
Collaborators
48
Papers, trials and grants by year

2015: 1 paper · 2016: 3 papers · 2017: 5 papers · 2018: 2 papers · 2019: 1 paper

Papers 12

  1. ABO Blood Group and the Risk of Pancreatic Neoplasms in Chinese Han Population: A Study at Shanghai Pancreatic Cancer Institute. Co-author DOI 10.1097/mpa.0000000000001408↗
  2. TCF7L2 positively regulates aerobic glycolysis via the EGLN2/HIF-1α axis and indicates prognosis in pancreatic cancer. Co-author DOI 10.1038/s41419-018-0367-6↗
  3. dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer. Co-author DOI 10.1111/cpr.12456↗
  4. ARF6, induced by mutant Kras, promotes proliferation and Warburg effect in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2016.12.014↗
  5. Oncogenic KRAS Targets MUC16/CA125 in Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/1541-7786.mcr-16-0296↗
  6. A new facet of NDRG1 in pancreatic ductal adenocarcinoma: Suppression of glycolytic metabolism. Co-author DOI 10.3892/ijo.2017.3938↗
  7. FBW7 increases the chemosensitivity of pancreatic cancer cells to gemcitabine through upregulation of ENT1. Co-author DOI 10.3892/or.2017.5856↗
  8. Diagnostic Accuracy of a CA125-Based Biomarker Panel in Patients with Pancreatic Cancer: A Systematic Review and Meta-Analysis. Co-author DOI 10.7150/jca.18901↗
  9. Metabolic plasticity in heterogeneous pancreatic ductal adenocarcinoma. Co-author DOI 10.1016/j.bbcan.2016.09.001↗
  10. Energy sources identify metabolic phenotypes in pancreatic cancer. Co-author DOI 10.1093/abbs/gmw097↗
  11. The clinical utility of CA125/MUC16 in pancreatic cancer: A consensus of diagnostic, prognostic and predictive updates by the Chinese Study Group for Pancreati… First author DOI 10.3892/ijo.2015.3316↗
  12. Metabolic tumor burden: a new promising way to reach precise personalized therapy in PDAC. Co-author DOI 10.1016/j.canlet.2015.01.023↗

Closest collaborators

The 25 strongest of 48 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Xianjun Yu · 12 shared papers, 2015–2019 · strength 0.72
  2. Wenyan Xu · 10 shared papers, 2016–2019 · strength 0.63
  3. Shunrong Ji · 10 shared papers, 2016–2019 · strength 0.63
  4. Yi Qin · 10 shared papers, 2016–2019 · strength 0.63
  5. Quanxing Ni · 11 shared papers, 2015–2018 · strength 0.63
  6. Jin Xu · 10 shared papers, 2015–2018 · strength 0.59
  7. Qiangsheng Hu · 8 shared papers, 2016–2018 · strength 0.48
  8. Chen Liang · 8 shared papers, 2016–2018 · strength 0.47
  9. Dingkong Liang · 8 shared papers, 2016–2018 · strength 0.47
  10. Si Shi · 8 shared papers, 2016–2018 · strength 0.47
  11. Bo Zhang · 3 shared papers, 2017–2018 · strength 0.20
  12. Wensheng Liu · 3 shared papers, 2017–2018 · strength 0.19
  13. Liang Liu · 4 shared papers, 2015–2017 · strength 0.19
  14. Qingcai Meng · 3 shared papers, 2017–2018 · strength 0.18
  15. Qiqing Sun · 2 shared papers, 2018–2019 · strength 0.16
  16. Chen Liu · 3 shared papers, 2015–2017 · strength 0.15
  17. Jiang Long · 2 shared papers, 2015–2017 · strength 0.10
  18. Mengqi Liu · 1 shared paper, 2019 · strength 0.09
  19. Xiaowu Xu · 1 shared paper, 2019 · strength 0.09
  20. Zheng Zhang · 1 shared paper, 2018 · strength 0.07
  21. Bo Zhang · 1 shared paper, 2018 · strength 0.07
  22. Pengfei Hu · 1 shared paper, 2017 · strength 0.05
  23. Huaxiang Xu · 1 shared paper, 2015 · strength 0.05
  24. Wenquan Wang · 1 shared paper, 2015 · strength 0.05
  25. Chuntao Wu · 1 shared paper, 2015 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.